前列地尔联合刺五加治疗糖尿病周围神经病变的临床观察

Study of Efficacy on Lipo PGE1 and Acanthopanax in Treatment of Diabetic Peripheral Neuropathy

目的探讨前列地尔（Lipo PGE1，凯时）联合刺五加治疗糖尿病周围神经病变的作用及其不艮反应。方法选取80例糖尿病周围神经病变患者，随机分为观察组（前列地尔＋刺五加）40例，对照组（刺五加）40例。两组控制血糖方法相同，对照组给予刺五加注射液（每支20ml含总黄酮100mg）40-60ml加入生理盐水250ml中静脉滴注，每天1次；观察组给予刺五加注射液（每支20ml含总黄酮100mg）40～60ml加入生理盐水250ml中静脉滴注＋前列地尔10ug静脉滴注，每天1次，两组疗程均为4周，观察其对神经传导速度（SNCV、MNCV）的影响。蛄果治疗4周后，患者主观症状和体征有较明显改善，前列地尔联合刺五加治疗糖尿病周围神经病变总有效率为82．5％，对照组总有效率为55．0％，两组疗效比较，有显著差异性（P〈0．01）。同时改善神经传导速度，两组疗效比较，有显著差异性（P〈0．01）。药物治疗过程中未见明显不良反应。结论前列地尔联合刺五加是治疗糖尿病周围神经病变安全且有效的药物。

Objective To observe the effects of Lipo PGE1 and acanthopanax in the treatment of diabetic peripheral neuropathy and side reactions. Methods 80 patients with early diabetic peripheral neuropathy were divided randomly into the treatment group with PGEI 10 μ g and acanthopanax Inj 40-60mi daily for 4 weeks, and acanthopanax group with acanthopanax Inj 40-60ml daily for 4 weeks in order to observe nerve conduction velocity. Results After treatment for 4 weeks, the subjective symptoms and signs were significantly improved with a total effective rate of 82.5% in the treatment group versus 55% in the control group, Compared with the acanthopanax group, the total effective rates of treatment group was significantly higher （P〈0. 01）,and improved significantly nerve conduction velocity（P〈0. 01）.No obvious adverse drug reactions were observed. Conclusion LipoPGE1 and acanthopanax is an effective and safe agent for treatment of diabetic peripheral neuropathy.